Pfizer Inc., Groton, Connecticut, USA.
Janssen Research & Development, Beerse, Belgium.
Toxicol Pathol. 2023 Jun;51(4):216-224. doi: 10.1177/01926233231182115.
The European Society of Toxicologic Pathology (ESTP) initiated a survey through its Pathology 2.0 workstream in partnership with sister professional societies in Europe and North America to generate a snapshot of artificial intelligence (AI) usage in the field of toxicologic pathology. In addition to demographic information, some general questions explored AI relative to (1) the current status of adoption across organizations; (2) technical and methodological aspects; (3) perceived business value and finally; and (4) roadblocks and perspectives. AI has become increasingly established in toxicologic pathology with most pathologists being supportive of its development despite some areas of uncertainty. A salient feature consisted of the variability of AI awareness and adoption among the responders, as the spectrum extended from pathologists having developed familiarity and technical skills in AI, to colleagues who had no interest in AI as a tool in toxicologic pathology. Despite a general enthusiasm for these techniques, the overall understanding and trust in AI algorithms as well as their added value in toxicologic pathology were generally low, suggesting room for the need for increased awareness and education. This survey will serve as a basis to evaluate the evolution of AI penetration and acceptance in this domain.
欧洲毒理学病理学学会(ESTP)通过其病理学 2.0 工作流与欧洲和北美的姐妹专业学会合作,发起了一项调查,以了解毒理学病理学领域人工智能(AI)的使用情况。除了人口统计信息外,一些一般性问题还探讨了 AI 相对于(1)组织内的采用现状;(2)技术和方法方面;(3)感知的商业价值;最后是(4)障碍和观点。尽管存在一些不确定因素,但 AI 在毒理学病理学中已经越来越成熟,大多数病理学家都支持其发展。一个显著的特点是,应答者之间的 AI 意识和采用程度存在差异,从对 AI 有一定了解和技术技能的病理学家,到对 AI 作为毒理学病理学工具不感兴趣的同事,范围广泛。尽管对这些技术普遍感到热情,但对 AI 算法的整体理解和信任,以及它们在毒理学病理学中的附加值普遍较低,这表明需要提高认识和教育。这项调查将作为评估该领域 AI 渗透和接受程度演变的基础。